Anti-aging medicine, once viewed as a fringe specialty, could gradually become part of mainstream healthcare as medical research increasingly focuses on preventing, delaying and potentially reversing aspects of age-related disease.

The shift is already beginning to take shape. A growing longevity industry is translating findings from laboratory research into clinical studies, while physicians, researchers and health systems are exploring new approaches to extending healthspan, the years of life spent in good health, with preserved physical and cognitive function.

The transition is unlikely to happen overnight. In its early stages, longevity medicine may look less revolutionary than its name suggests, focusing on familiar areas such as healthier lifestyles, weight management, prevention and medicines being investigated for their potential effects on aging-related biology. More transformative therapies could emerge later, if ongoing research demonstrates that they are safe, effective and capable of improving meaningful patient outcomes.

Italy offers a glimpse of what could come next

Italy provides a particularly important case study. The country has one of the world’s oldest populations, with people aged 65 and over accounting for 24.1% of the population, the highest proportion in the European Union. Life expectancy is high; 85.4 years for women and 81.4 years for men, but the number of years people live in good health is substantially lower, at 69.6 and 68.5 years respectively.

The gap between lifespan and healthspan presents a growing challenge. More than 60% of adults aged 75 and over experience multimorbidity or disability, placing increasing demands on patients, families and the healthcare system.

Against this demographic backdrop, a new position paper examining the integration of healthspan strategies into Italy’s National Health Service argues that healthcare systems may need to move beyond a predominantly reactive, hospital-centered model toward earlier and more systematic prevention.

The paper describes longevity medicine as an emerging prevention-oriented discipline that combines approaches including biological and multi-omic biomarkers, digital health monitoring, life-course risk assessment and new clinical-trial methodologies. However, its authors stress that many of these technologies remain experimental or rely on surrogate measures, and that their clinical usefulness has yet to be firmly established.

Five priorities for a longevity-focused health system

The authors propose five areas for strategic investment:

1. Clinically validated biomarkers of biological age to improve assessment of age-related risk.
2. Interoperable digital monitoring systems capable of tracking health and risk over time.
3. Adaptive multimodal clinical trials designed to evaluate complex prevention strategies more efficiently.
4. Explainable artificial-intelligence tools to support individual risk assessment and stratification.
5. Longevity-focused medical education to prepare healthcare professionals for an increasingly prevention-oriented model of care.

The proposals are presented as a staged agenda rather than an established blueprint. Their value, the authors argue, should ultimately be judged by whether they produce measurable improvements in patient outcomes, are practical to implement and represent good value for healthcare spending.

Demographics could accelerate the transformation

The potential expansion of longevity medicine is being driven by more than scientific enthusiasm. As populations age, governments face rising rates of chronic disease, disability and healthcare expenditure. Extending healthy years of life could therefore become an important public-health and economic objective, provided interventions can demonstrate real-world benefits.

This could gradually change the role of anti-aging medicine itself. What is now a relatively small specialty could evolve into a broader medical framework in which physicians routinely manage the prevention and treatment of age-related decline.

The most significant change may ultimately be cultural rather than technological: medicine could increasingly focus not only on treating diseases after they appear, but on identifying and modifying the processes and risks that make those diseases more likely in the first place.

For now, many of the tools associated with longevity medicine remain under investigation. But as populations continue to age and research advances, the boundary between “anti-aging medicine” and conventional healthcare may become increasingly difficult to define.

The question may no longer be whether longevity medicine will enter mainstream healthcare, but how much of mainstream healthcare will eventually become longevity medicine.